# Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

> **NCT02611817** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 644 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Vedolizumab SC 108 mg
- **DRUG:** Placebo
- **DRUG:** Vedolizumab IV 300 mg

## Key facts

- **NCT ID:** NCT02611817
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-04
- **Primary completion:** 2019-05-06
- **Final completion:** 2019-08-06
- **Target enrollment:** 644 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611817, "Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02611817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*